Sjögren's Disease Clinical Trial Monitor — BAFF Inhibitor & B-Cell Programs 2026

The Sjögren's disease trial landscape in 2026

Sjögren's disease — renamed from "Sjögren's syndrome" in recent years to reflect its systemic nature — remains the last major autoimmune disease without a single approved disease-modifying therapy. Despite affecting an estimated 4 million Americans (predominantly women), the indication has historically had sparse clinical trial activity and repeated high-profile Phase 3 failures, including rituximab and abatacept trials.

That is now changing dramatically. The field has learned from past failures: better patient stratification, validated biomarkers (anti-SSA/SSB positivity, systemic disease activity via ESSDAI), and a new wave of mechanism-specific therapies. As of 2026, there are 37+ active studies with multiple Phase 3 programs in active enrollment. The first approved therapy will enter a massive unmet need market with no established standard of care — creating commercial potential comparable to early IL-17 inhibitors in psoriasis or dupilumab in atopic dermatitis.

The race for the first FDA approval in Sjögren's disease

Three Phase 3 programs are currently the leading contenders for the first FDA approval in Sjögren's disease:

Ianalumab (VAY736, Novartis) — anti-BAFF-R

Ianalumab is a monoclonal antibody that blocks the BAFF receptor (BAFF-R) on B cells, depleting mature B cells while sparing plasma cells and early B-cell progenitors. Novartis is running three Phase 3 studies:

• NCT05349214 — Phase 3 efficacy and safety study in Sjögren's disease
• NCT05350072 — Phase 3 study with focus on systemic manifestations
• NCT05985915 — Open-label extension study

The BAFF-R targeting approach is mechanistically distinct from anti-BAFF antibodies (which include belimumab, approved in lupus): by blocking the receptor rather than the ligand, ianalumab may provide more complete B-cell depletion.

Dazodalibep (AMG 557/HZN-4920, Amgen) — CD40L/ICOS costimulation inhibitor

Dazodalibep targets the ICOS/ICOS-L costimulatory axis that drives pathogenic T cell-B cell interactions in Sjögren's disease. Phase 2 data showed significant improvements in ESSDAI and patient-reported outcomes. Amgen's Phase 3 study (NCT06104124) is a key event for the field — a mechanistically distinct approach that doesn't directly deplete B cells but disrupts the T cell help that drives autoimmune activation.

Nipocalimab (Janssen/J&J) — anti-FcRn

Nipocalimab is an antibody targeting the neonatal Fc receptor (FcRn), which recycles IgG antibodies (including pathogenic anti-SSA/SSB antibodies) and extends their half-life. By blocking FcRn, nipocalimab rapidly lowers IgG levels across all subtypes, including the autoantibodies central to Sjögren's disease pathogenesis. Janssen's Phase 3 study (NCT06741969) is a major trial to monitor. Nipocalimab is already in Phase 3 for myasthenia gravis and other autoantibody-driven diseases, so Sjögren's data will be read in the context of a broader FcRn program.

Key mechanisms: BAFF inhibition, B-cell depletion, FcRn, and beyond

BAFF/BAFF-R inhibition

BAFF (B-cell activating factor) is overexpressed in Sjögren's disease salivary and lacrimal gland tissue, promoting survival and differentiation of autoreactive B cells. Ianalumab (anti-BAFF-R) and belimumab (anti-BAFF, already approved in lupus and lupus nephritis) both target this pathway. Sjögren's patients with elevated BAFF levels and systemic disease are thought to be the most likely responders.

B-cell depletion: rituximab and next-generation agents

While rituximab (anti-CD20) Phase 3 trials in Sjögren's disease failed on primary endpoints, more recent programs are targeting earlier-line treatment, anti-SSA+ enriched populations, and patients with higher baseline disease activity. Obinutuzumab and other next-generation anti-CD20 agents are in earlier development for Sjögren's.

FcRn inhibition: rapid IgG reduction

The FcRn mechanism is gaining traction across multiple autoantibody-mediated diseases. In addition to nipocalimab (Janssen), argenx's efgartigimod is in the Sjögren's pipeline. FcRn inhibitors offer the advantage of reducing all IgG subtypes rapidly and reversibly, making them suitable for patients with high autoantibody burden and active systemic disease.

CD40/ICOS costimulation blockade

Dazodalibep's mechanism targets the "second signal" in T cell activation — the ICOS/ICOS-L costimulatory interaction that amplifies B cell help. This approach aims to break the T-B cell collaboration that perpetuates autoimmune inflammation without broadly depleting B cells, potentially offering a more targeted and durable effect.

Plasmacytoid dendritic cells and TLR inhibition

pDCs are major producers of type I interferons in Sjögren's disease, and TLR7/8/9 agonism drives aberrant pDC activation. Emerging programs targeting pDC biology and TLR inhibition represent the next mechanistic frontier, with early-phase studies in active development.

Phase 3 spotlight: key Sjögren's disease trials

NCT ID	Sponsor	Drug / Intervention	Phase	Mechanism	Status
NCT05349214	Novartis	Ianalumab (VAY736) — anti-BAFF-R	Phase 3	BAFF-R / B-cell depletion	Recruiting
NCT05350072	Novartis	Ianalumab (VAY736) — systemic manifestations study	Phase 3	BAFF-R / B-cell depletion	Recruiting
NCT05985915	Novartis	Ianalumab (VAY736) — open-label extension	Phase 3 OLE	BAFF-R / B-cell depletion	Active
NCT06104124	Amgen	Dazodalibep — CD40L/ICOS costimulation inhibitor	Phase 3	ICOS/ICOS-L costimulation blockade	Recruiting
NCT06741969	Janssen (J&J)	Nipocalimab — anti-FcRn (IgG reduction)	Phase 3	FcRn inhibition / IgG reduction	Recruiting
Pipeline	argenx	Efgartigimod — anti-FcRn	Phase 2/3 (planned)	FcRn inhibition / IgG reduction	In development

Top sponsors in Sjögren's disease

• Novartis — Most active sponsor with 3 Phase 3 ianalumab studies; dominant early-mover position in Sjögren's; cross-indication immunology franchise strategy.
• Amgen — Phase 3 dazodalibep; distinct ICOS costimulation mechanism; Phase 2 data were among the most promising in the indication's history.
• Janssen (J&J) — Nipocalimab Phase 3; FcRn platform being deployed across multiple autoantibody-driven diseases; Sjögren's is a key indication in a broader franchise strategy.
• argenx — Efgartigimod in pipeline; FcRn competitor to nipocalimab with existing approval in myasthenia gravis (VYVGART); multi-indication expansion underway.

Why competitive monitoring matters in this indication

Sjögren's disease presents a unique competitive intelligence challenge. The indication has been plagued by Phase 3 failures, which means sponsors are being highly strategic about patient selection, endpoint choice (ESSDAI for systemic disease vs. ESSPRI for patient-reported outcomes vs. composite endpoints), and trial design. Small changes in competitor trial protocols carry outsized strategic significance:

• Endpoint changes: A protocol amendment changing from ESSDAI to a composite endpoint — or adding patient-reported dryness — signals how a sponsor is repositioning after regulatory feedback. These changes appear in ClinicalTrials.gov protocol updates before any press release.
• Enrollment expansions and stratification: Adding or removing anti-SSA antibody positivity as an entry criterion directly affects who can enroll. A competitor tightening entry criteria signals they believe the anti-SSA+ population is the more responsive subgroup.
• Enrollment completion timing: Ianalumab's completion schedule affects when Novartis will seek approval — creating a timeline pressure that shapes AbbVie, Amgen, and Janssen's own resource allocation decisions.
• New entries: The pDC and TLR inhibitor pipeline for Sjögren's is early-stage but growing. A major pharma sponsor entering Phase 2 in Sjögren's signals a medium-term competitive threat that BD teams want to see early.

DataLookout monitors all Sjögren's disease programs on ClinicalTrials.gov daily, delivering field-level change alerts — including endpoint, enrollment, sponsor, and protocol changes — directly to your inbox.

Related autoimmune and immunology trial monitors

• Lupus clinical trials — overlapping BAFF, B-cell, and FcRn mechanisms; shared patient populations and sponsor portfolios
• Myasthenia gravis clinical trials — FcRn inhibitor programs (efgartigimod, nipocalimab) competing in both indications
• Rheumatoid arthritis clinical trials — shared biologic platforms and mechanism overlap with B-cell targeted therapies
• IgA nephropathy clinical trials — BAFF/APRIL pathway overlap; anti-FcRn programs relevant across both indications